One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and ...
A novel HIV vaccine candidate induces neutralising antibodies after a single dose in primates, potentially accelerating HIV ...
The Democratic Alliance (DA) is thrilled by the news of vaccine trials for HIV. While in an early trial phase, this shows ...
Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in ...
So far, there is no "magic bullet" to cure HIV for good, but scientists are making rapid progress.
South Africa has begun the first human trials of a locally developed HIV vaccine to defeat a virus that still kills around ...
The BRILLIANT 011 trial is testing two next-generation HIV vaccine components—BG505 GT1.1 and 426c.Mod.Core-C4b—administered ...
Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.
The BRILLIANT 011, a first-in-human clinical trial, was officially launched at the Desmond Tutu HIV Foundation (DTHF) ...
An African-led research initiative working to develop an HIV vaccine, under the aegis of The BRILLIANT Consortium, has launched the BRILLIANT 011 trial at the Desmond Tutu Health Foundation in Cape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results